Uric acid and decline in renal function-partners in crime by Dawson, Jesse & Mark, Patrick B.
  
 
 
 
 
Dawson, J., and Mark, P. B. (2017) Uric acid and decline in renal function-partners in 
crime. American Journal of Nephrology, 45(4), pp. 327-329. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/138229/ 
     
 
 
 
 
 
 
Deposited on: 14 March 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Uric acid and decline in kidney function- partners in crime without any alibi 
 
 
Jesse Dawson1 & Patrick B. Mark1   
 
1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Clinical Research Centre, 
University of Glasgow, Glasgow, United Kingdom 
 
 
Uric acid is a breakdown product of purine metabolism, regulated by the enzyme 
xanthine oxidase (XO). Pre-clinical studies suggest hyperuricaemia induces 
hypertension, renal microvascular disease and endothelial dysfunction and that it 
causes triglyceride accumulation in response to fructose ingestion [1]. XO may have 
further, uric acid independent, effects on the CV system. XO action generates 
superoxide, which has a role in renin-angiotensin system activation, in detrimental 
responses to fructose ingestion, and in ischaemia-reperfusion injury. 
In this paper Kuwibara and colleagues [2] explored the relationship between serum 
uric acid level and change in estimated glomerular filtration rate (eGFR) over a 5-
year period in a single centre retrospective cohort study. This was a well conducted 
analysis including over 13,000 Japanese patients. Higher baseline serum uric acid 
level was associated with greater odds of rapid eGFR decline (OR 1.27, 9%% CI 
1.17-1.38 for each 1 mg/dl increment in serum uric acid. The authors were able to 
adjust for numerous potential confounders including age, body mass index, 
cardiovascular risk factors and diabetes status but were not able to account for 
difference in medication use or the presence or absence of proteinuria. The analyses 
were stratified by sex and sub-analyses stratified by baseline eGFR found similar 
results. This association has been shown before in Japanese patients and in patients 
with treated hypertension in the UK [3]. A novel finding from this study was that an 
increase in serum uric acid over a 5-year period was associated with a greater 
decline in eGFR (OR 3.77, 95% CI 3.35m to 4.26 for each 1mg/dl increase). Whilst, 
as the authors acknowledge, dissecting an independent effect of uric acid on decline 
in eGFR is challenging, independent of any influence of reducing kidney function on 
serum urate.  Taken together, the epidemiological data are consistent, large in scale 
and suggest serum uric acid is associated with development of cardiovascular, renal 
and metabolic disease. However, these data cannot however prove causality. 
Experimental data support causality. Induction of hyperuricaemia causes a decline in 
renal function, glomerular hypertension and a small vessel renal arteriopathy in 
rodent models. This may be mediate reno-vascular disease via increased renin 
production, COX-2 expression and thromboxane production [1]. 
One method of trying to better assess causality in humans is via use of Mendelian 
Randomization studies. Here, the relationship between a genetic polymorphism 
known to affect the exposure of interest (in this case uric acid level) and outcome is 
explored. This association should not be susceptible to confounding or reverse 
causation as presence of the phenotype of interest will be randomly determined at 
conception. Previous Mendelian Randomization studies have failed to demonstrate a 
clear association between instrumental variables for serum uric acid and chronic 
kidney disease and in one study, the instrumental variable was associated with 
better renal function in men [4]. Mendelian Randomization studies in this setting 
have numerous challenges. Several genes are associated with serum uric acid 
levels with renal urate transports accounting for most of the variance. Renal 
transport of serum uric acid is complex and it may be that activity of the transporters 
is related to renal function, rather than serum uric acid level itself. The mechanism of 
hyperuricaemia and whether intracellular levels are raised may be important with 
regard to the risk conveyed and our understanding of how this affects reported 
epidemiological relationships, or how it is affected by genotype, is limited. It is worth 
noting that a number of genes associated with chronic kidney disease in genome 
wide association studies are also associated with serum uric acid level. 
So epidemiological and experimental data suggest hyperuricaemia may contribute to 
renal function decline but findings from Mendelian Randomization studies leave this 
open to debate. The more important question for clinicians is whether uric acid 
reduction slows decline in renal function and whether this reduction is sufficient to 
translate into either a reduction in progression to end stage renal disease (ESRD), 
requiring dialysis or transplantation, or a reduction in the increased cardiovascular 
risk associated with chronic kidney disease (CKD). Studies have reported an effect 
of allopurinol, the most widely used uric acid lowering drug, on renal function since 
the 1970s. It is important to recognize that xanthine oxidase inhibitors have been 
observed to have clear pleotropic effects such as improving endothelial function. 
Allopurinol is metabolised to oxypurinol, a purine analogue, which is a competitive 
inhibitor of xanthine oxidase. It lowers serum uric acid in a dose dependent fashion 
but also reduces formation of reactive oxygen species. Serum uric acid level can 
also be lowered by uricosuric drugs, such as probenecid, which do not directly 
reduce oxidative stress. Thus, an observed effect of allopurinol cannot be assumed 
to be due to uric acid reduction. 
Clinical trials do suggest that allopurinol improves renal function or halts decline in 
renal function. Although many of the early reports were from uncontrolled or open 
studies, data from randomised and blinded trials are emerging. However, these 
studies have typically been small. Meta-analysis of these small studies (8 trials, 
n=476) showed only a difference in change in serum creatinine and but not change 
in eGFR [5]. There is as yet no evidence that allopurinol use will reduce rates of 
progression to ESRD. This has not been adequately studied, rather than adequately 
powered trials failing to demonstrate effect. There are also insufficient data to draw 
conclusion about the effect of probenecid in the setting of CKD, and whilst it may be 
an ineffective uricosuric in CKD, trials testing allopurinol compared to allopurinol in 
patients with heart failure showed that allopurinol 600 mg (n=30) and not probenecid 
(n=26) improved forearm endothelial function [6] despite similar degrees of uric acid 
reduction. The cardiovascular effects of allopurinol at least may not be mediated via 
uric acid reduction. 
No large trials of cardiovascular outcomes exist in patients with CKD, although data 
support the need for these to be performed. In a randomized, double-blind, placebo-
controlled, parallel-group study in patients with stage 3 CKD and left ventricular 
hypertrophy (LVH), allopurinol 300 mg daily reduced LVH and improved endothelial 
function over a 9-month treatment period [7]. LVH is an independent predictor of 
stroke and other cardiovascular events and LVH regression appears beneficial. This 
raises the possibility that allopurinol will improve CV outcomes in patients with CKD. 
This notion is being tested in double blind placebo controlled trial of allopurinol in 
hemodialysis patients, aiming to regress LVH (clinicaltrials.gov NCT01951404). 
The paper by Kuwibara et al is an important step forward. It adds fuel to fire 
surrounding the importance of uric acid in cardiovascular and renal disease - a fire 
that has burned for over half a century. We need now to conduct thoughtful 
prospective interventional studies of uric acid reduction. Large-scale trials are 
needed to assess the affect of XO inhibition on meaningful clinical outcomes in 
patients with CKD, such as progression to ESRD or cardiovascular outcomes. XO 
inhibitors have the most data to support conduct of large scale trials but smaller 
trials, perhaps with change in eGFR as an endpoint, are also needed to compare the 
effects of XO inhibition and uricosuric drugs. This will establish whether effects in 
renal disease are uric acid mediated, or due to other pleotropic effects. 
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